Account plan di Danone
Leader globale nell'alimentazione e nella salute
In sintesi
Danone è un gruppo alimentare francese di latticini, vegetale, nutrizione specializzata e acque: 27.283 milioni di euro di vendite 2025, 88.670 dipendenti.
La missione di Danone è portare la salute attraverso l'alimentazione al maggior numero possibile di persone, attraverso tre categorie: Essential Dairy & Plant-Based, Specialized Nutrition (latte in polvere per l'infanzia e nutrizione medica) e Waters. Tra i suoi marchi figurano Activia, Actimel, Oikos, Alpro, Silk, Aptamil, Nutricia, evian e AQUA, venduti attraverso catene della grande distribuzione, punti vendita tradizionali, e-commerce, fuori casa e canali specializzati come ospedali e farmacie. Nel 2025 le vendite sono state di 27.283 milioni di euro (+4,5% a parità di perimetro), il reddito operativo ricorrente di 3.665 milioni di euro (margine del 13,4%) e l'utile netto di competenza del gruppo di 1.825 milioni di euro. Al 31 dicembre 2025 contava 88.670 dipendenti e 151 siti produttivi. Gilles Schnepp presiede il Consiglio di amministrazione e Antoine de Saint-Affrique è CEO.
Divisioni
Essential Dairy & Plant-Based (EDP)
48% delle vendite 2025 (13.158 milioni di euro)Yogurt, creazioni al caffè, dessert e bevande e alternative vegetali con i marchi Activia, Actimel, Danone, Oikos, YoPro, Alpro e Silk. La crescita 2025 è stata del +3,5% a parità di perimetro con un margine dell'8,5%; high protein, Skyr e kefir crescono a due cifre mentre il Nord America è in fase di rilancio. Le vendite del H1 2026 sono state di 6.681 milioni di euro, con il margine sceso al 7,1% perché l'inflazione ha superato i prezzi.
Specialized Nutrition
34% delle vendite 2025 (9.277 milioni di euro)Latte in polvere per l'infanzia, alimentazione complementare e nutrizione medica pediatrica e per adulti (Aptamil, Nutricia, Neocate, Fortimel, Nutrison, Kate Farms), venduti in parte tramite ospedali e farmacie. È cresciuta del +7,4% a parità di perimetro nel 2025 con un margine del 21,7%, il più alto tra le categorie; le vendite del H1 2026 sono state di 4.730 milioni di euro. Guidata da Jean-Marc Magnaudet, President Specialized Nutrition.
Waters
18% delle vendite 2025 (4.848 milioni di euro)Acque naturali, aromatizzate e funzionali con i marchi evian, Volvic, AQUA, Mizone e Bonafont. La crescita 2025 è stata del +1,9% a parità di perimetro con un margine del 10,9%; le vendite del H1 2026 sono state di 2.525 milioni di euro con un margine del 13,3%, con Mizone debole in Cina.
Area EMEA
6.133 milioni di euro di vendite nel H1 2026Europa, Turchia, Medio Oriente, Africa e CSI, la più grande area dopo la riorganizzazione di gennaio 2026. La crescita del H1 2026 è stata del +2,1% a parità di perimetro con un margine del 10,4% nonostante il richiamo del latte in polvere per l'infanzia. Presidente: Pablo Perversi.
Area Americhe
4.688 milioni di euro di vendite nel H1 2026Nord e America Latina, compresa la piattaforma statunitense di nutrizione medica costruita con Kate Farms. La crescita del H1 2026 è stata del +3,9% a parità di perimetro con un margine del 9,6%; il rilancio di yogurt, creamer e prodotti vegetali negli Stati Uniti è in corso. Presidente: Henri Bruxelles.
Area APAC
3.116 milioni di euro di vendite nel H1 2026Cina, Giappone, Australia, Nuova Zelanda, Indonesia, Thailandia, Vietnam e India, per due terzi Specialized Nutrition. La crescita del H1 2026 è stata del +5,6% a parità di perimetro con un margine del 24,7%. Presidente: Bruno Chevot.
Priorità strategiche
- Rinnovare Danone Chapter 2
- Spostare le categorie (dallo yogurt alla salute intestinale e alle proteine, dal vegetale al plant-powered, dalle acque all'idratazione sana), ampliare modelli di business come homecare e fuori casa, ed espandersi negli Stati Uniti, in India e nel Sud-Est asiatico.
- Modello finanziario a medio termine
- Per il 2025-2028: crescita delle vendite a parità di perimetro del 3-5%, reddito operativo ricorrente in crescita più delle vendite, ROIC strutturalmente a due cifre e progressi verso 3 miliardi di euro di free cash flow sostenibile. La guidance 2026 rientra in questo intervallo.
- Risanare il Nord America
- Aggiungere capacità produttiva di yogurt linea per linea in 13 stabilimenti, rilanciare Activia nel H2 2026, entrare nel kefir negli Stati Uniti e rilanciare il marchio Dannon con un nuovo approccio al greco a inizio 2027, portando Silk verso il modello Alpro.
- Far crescere la nutrizione medica
- Kate Farms con Nutricia forma una piattaforma statunitense di nutrizione medica da 500 milioni di dollari; in Cina Danone punta a una penetrazione ospedaliera più profonda oltre le città di fascia 1.
- Canali strategici e IA
- I canali diversi dalla grande distribuzione superano il 50% delle vendite e crescono da 2 a 3 volte più rapidamente; l'IA viene estesa da Microsoft Copilot per tutti alla supply chain, alla R&S e al rapporto con i distributori.
Ultimi risultati
Nel H1 2026 (sei mesi chiusi il 30 giugno 2026) le vendite sono state di 13.936 milioni di euro, in crescita del 3,5% a parità di perimetro e dell'1,4% a dati reali, con una crescita a parità di perimetro del 4,2% nel Q2. Il reddito operativo ricorrente è salito del 2,3% a 1.854 milioni di euro e il margine al 13,3% (+12 punti base), perché la produttività dei costi generali ha compensato il richiamo del latte in polvere per l'infanzia e i primi effetti inflazionistici del conflitto in Medio Oriente. L'utile netto di competenza del gruppo è salito del 13,0% a 1.175 milioni di euro. Il free cash flow è sceso a 852 milioni di euro da 1.172 milioni di euro perché Danone ha costituito scorte di sicurezza, e l'indebitamento netto è salito a 8.975 milioni di euro. È stata confermata la guidance 2026 di una crescita a parità di perimetro dal 3% al 5%, con reddito operativo ricorrente in crescita più delle vendite.
Investimenti e operazioni
- Kate Farms
- Quota del 96% acquisita il 1° luglio 2025 per 839 milioni di euro (983 milioni di dollari), un marchio statunitense di nutrizione medica e quotidiana a base vegetale che entra nel perimetro comparabile dal Q3 2026.
- Huel
- Accordo definitivo del 23 marzo 2026 per acquisire il marchio di nutrizione completa, con forti vendite dirette al consumatore nel Regno Unito, in Europa e negli Stati Uniti; chiusura prevista nel H2 2026.
- MADE Group e la joint venture lattiero-casearia in Australia
- Accordo del 22 giugno 2026 per acquistare MADE Group, con sede a Melbourne (più di 300 milioni di euro di vendite), e il restante 49% di Danone Saputo Dairy Australia, che insieme aggiungerebbero più di 400 milioni di euro di vendite in APAC.
- Joint venture in Argentina e cessioni
- Un accordo del 24 marzo 2026 con Arcor unisce Danone Argentina e Mastellone Hermanos in una joint venture a governance congiunta; Proviva e Lunnarp in Svezia sono state vendute il 2 marzo 2026.
- Capex per la capacità produttiva
- Il capex è stato di 1.055 milioni di euro nel 2025 e di 414 milioni di euro nel H1 2026, per capacità high protein e di nutrizione medica, e potrebbe salire al 4,5% delle vendite.
Sfide e rischi
- Richiamo del latte in polvere per l'infanzia
- Il richiamo di gennaio 2026 in Europa e Medio Oriente ha comportato 42 milioni di euro di costi non ricorrenti nel H1 2026 e ha generato azioni legali in diverse giurisdizioni; l'Europa resta un quadro con luci e ombre.
- Conflitto in Medio Oriente e inflazione dei costi
- Il conflitto perturba la logistica nella regione e fa salire i costi di energia, trasporto, imballaggi e di alcune materie prime; il margine EDP è sceso di 68 punti base nel H1 2026 prima degli aumenti di prezzo.
- Competitività di EDP negli Stati Uniti
- Il CEO si è dichiarato insoddisfatto di parti del portafoglio EDP nordamericano: creamer per caffè, vegetale (Silk) e yogurt non proteici privati di capacità.
- Dipendenza dalla Cina
- La Cina vale circa il 12% delle vendite ed è il maggiore contributore al profitto, e il latte in polvere per l'infanzia venduto lì è per lo più prodotto all'estero; Mizone ha pesato nel Q2 2026.
Cosa dice il management
“the food industry is at a tipping point and health through food has never been more relevant”
“It is clear that in the US, our performance in 2025 didn't meet our expectations. We are not where we should be, and we know we need to step up our game.”
“Protein is here to stay. Penetration of GLP-1 is still nowhere”
“volume, volume, volume and mix will remain our priority number one”
Dove un fornitore può aiutare
- Resilienza della supply chain
- Le scorte di sicurezza costituite contro le perturbazioni in Medio Oriente e i maggiori costi di imballaggi ed energia rendono rilevanti i fornitori di pianificazione, approvvigionamento e ottimizzazione logistica.
- Aumento della capacità negli Stati Uniti
- Il risanamento del Nord America dipende dall'aggiunta di capacità di yogurt linea per linea in 13 stabilimenti: fornitori di attrezzature, automazione e manufacturing execution system si adattano a questa priorità.
- Marketing diretto al consumatore e di community
- Huel porta competenze direct-to-consumer e di community che Danone dichiara di non avere; strumenti di e-commerce, contenuti e community management possono sostenere l'integrazione e la spinta verso i canali strategici.
- Accesso al canale sanitario
- Far crescere la nutrizione medica tramite ospedali, farmacie e operatori sanitari negli Stati Uniti e in Cina richiede partner per sales enablement medicale, economia sanitaria e coinvolgimento degli operatori sanitari.
Lettura di Tamtam delle priorità e delle sfide qui sopra, non parole dell'azienda.
Vendi ad aziende come Danone?
Tamtam trova le aziende in linea con il tuo cliente ideale, analizza ogni account e ti dice chi contattare e quando.
Trova aziende similiDocumenti chiave
Letti per intero da Tamtam; ogni sintesi rimanda al documento originale.
- Universal Registration Document 2025 (Annual Financial Report)
- Danone is a health-focused food group with three categories: Essential Dairy & Plant-Based (EDP, 48% of 2025 sales, €13,158m), Specialized Nutrition (infant formula and medical nutrition, 34%, €9,277m) and Waters (18%, €4,848m). It is no. 1 worldwide in fresh dairy and in plant-based foods and beverages, no. 2 in packaged waters and early life nutrition, no. 4 in adult medical nutrition. 88,670 employees and 151 production sites at end 2025.
- FY2025: sales €27,283m, +4.5% like-for-like (volume/mix +2.7%, price +1.8%) but -0.3% reported after a -5.0% currency effect; recurring operating income €3,665m, margin 13.4% (+44 bps); recurring EPS €3.80 (+4.6%); free cash flow €2,799m; ROIC 10.7% (+62 bps); dividend €2.25 (+4.7%). Reported net income fell 9.7% to €1,825m because of €725m of non-recurring costs (transformation projects in Europe and Indonesia, impairments).
- Growth by zone (LFL): Europe +2.3% (36% of sales), North America +2.0% (23%, "softer growth"), China, North Asia & Oceania +11.7% (14%, entirely volume/mix), Latin America +6.0%, Asia-Middle East-Africa +5.6%. By category: EDP +3.5% (margin 8.5%), Specialized Nutrition +7.4% (margin 21.7%, +112 bps), Waters +1.9% (margin 10.9%).
- The United States is the largest country (20% of sales), China second (12%, and the largest profit contributor); the top-5 markets are 51% of sales. The top ten customers are about 20% of sales, the top five about 14%. Channels outside mass retail (pharmacies, hospitals, homecare, away-from-home, e-commerce) are now over 50% of sales and grew 2-3x faster than mass retail in 2025.
- Strategy: "Renew Danone" Chapter 2 (since June 2024) pivots categories towards protein and gut health, broadens business models (away-from-home, medical nutrition, homecare), expands in the US, India and South-East Asia, and moves "to the front foot" on M&A. Mid-term guidance 2025-2028: 3-5% LFL sales growth, recurring operating income growing faster than sales, structurally double-digit ROIC, long-term ambition of €3bn free cash flow.
- 2025 M&A: 96% of Kate Farms (US plant-based medical nutrition, no. 1 doctor-recommended) for €839m ($983m) on July 1, 2025, creating a US medical nutrition platform; The Akkermansia Company (biotics, Belgium); disposal of the Iranian dairy business (€77m loss); sale of Proviva/Lunnarp (Sweden) signed. Capex rose to €1,055m, mostly capacity for high protein and medical nutrition.
- Organisation: from January 1, 2026 Danone runs three zones (EMEA, Americas, APAC) instead of five; Shane Grant (Deputy CEO, CEO Americas) left in June 2025. Early 2026 events: targeted recall of infant formula batches (January 23, 2026) and consolidation of the Australian dairy JV with Saputo at 51% (February 12, 2026).
- Main risks rated "strong": over-reliance on principal markets (notably China, where infant formula sold is mostly made abroad), packaging/plastics regulation, fast changes in consumer preferences, raw material and energy price volatility (materials are ~75% of COGS, about €10bn a year), climate change. Medium: retail shift (discounters, private label), currency, legal/regulatory, cybersecurity, food safety, talent, business transformation.
- 2026 guidance: like-for-like sales growth of 3% to 5% with recurring operating income growing faster than sales. CEO Antoine de Saint-Affrique: "there is more to do and some areas still require further progress."
- 2026 Interim Financial Report (six months ended June 30, 2026)
- H1 2026 sales €13,936m, +3.5% like-for-like (volume/mix +1.7%, price +1.8%), +1.4% reported with a +0.7% scope effect (Kate Farms, Australian dairy JV) and -3.3% from currencies.
- Recurring operating income €1,854m, margin 13.3% (+12 bps): strong productivity gains including +84 bps in overheads offset a -54 bps fall in margin from operations (infant formula recall in EMEA, first effects of inflation) and -25 bps of reinvestment in A&P, product superiority and capabilities.
- New three-zone reporting: EMEA €6,133m (+2.1% LFL, margin 10.4% flat), Americas €4,688m (+3.9%, margin 9.6%, +31 bps), APAC €3,116m (+5.6%, margin 24.7%). By category: EDP €6,681m (+3.6%, margin 7.1%, -68 bps), Specialized Nutrition €4,730m (+3.2%, margin 22.1%), Waters €2,525m (+3.6%, margin 13.3%, +196 bps).
- Recurring EPS €1.92 (+0.9%); reported net income group share €1,175m (+13.0%), helped by a €122m remeasurement gain on the Australian JV; non-recurring operating expense -€161m (transformation projects €82m, recall costs €42m).
- Free cash flow €852m (vs €1,172m): capex up to €414m and a -€567m working capital outflow from security stocks built up because of the Middle East situation. Net debt €8,975m (+€544m since December); €1.6bn triple-tranche bond issued in March; dividend of €2.25 paid in May (€1,440m).
- Deals signed and pending close in H2 2026: acquisition of Huel (complete nutrition, UK/Europe/US, direct-to-consumer), acquisition of MADE Group (Australia, >€300m sales, high-protein RTD, gut-health yogurts, coconut products) and of the remaining 49% of the Saputo dairy JV, and a dairy joint venture with Arcor in Argentina that deconsolidates Danone Argentina (assets held for sale €240m).
- Risks: no new risk factors, but the Middle East conflict that began in February 2026 is disrupting logistics and inflating energy, transport, packaging and some agricultural costs; the January 2026 infant formula recall has triggered claims in several jurisdictions, with no provision booked.
- 2026 guidance confirmed: like-for-like sales growth of 3% to 5% with recurring operating income growing faster than sales.
- H1 2026 results conference call transcript (CEO Antoine de Saint-Affrique, CFO Juergen Esser)
- Q2 2026 like-for-like sales +4.2% (volume/mix +1.9%, positive in every region and category), reported +4.4% to €7.2bn with scope +0.8% (Kate Farms, Australian JV) and currency -1%; H1 LFL +3.5%, recurring operating margin 13.3% (+12 bps), recurring EPS €1.92 (+0.9%), free cash flow €0.9bn.
- Q2 by category: EDP +3.8%, Specialized Nutrition +4.5% (medical nutrition strong everywhere; infant formula in Europe and the Middle East recovering since mid-Q2), Waters +4.7% (Volvic, Aqua Indonesia). By zone: EMEA +3.6%, Americas +4.3% (North America +2.6%), APAC +5.2% (Mizone down in a soft Chinese waters season).
- Growth engines: high protein double-digit in all regions, Skyr and Kefir double-digit in Europe, Alpro high single-digit, medical nutrition brands Nutrison, Fortimel and Neocate high single to double-digit; away-from-home, hospitals, pharmacies and home care grow 2-3x faster than mass retail.
- North America EDP: "still only at the beginning of the journey"; yogurt lines come on stream line by line through 2026, Activia relaunch in H2, Oikos new formats, International Delight renovation in 2027, Silk repositioned as "plant-powered" with protein yogurt and shakes; creamers have stabilised; "everything that is protein is absolutely absolutely flying".
- M&A under three filters (strategic fit, financial discipline with double-digit ROIC, execution capability): Huel (premium complete nutrition, direct-to-consumer and community skills, 300-400 digital assets a month), MADE Group plus the rest of the Australian JV (doubles APAC EDP, adds more than €400m of sales, accretive to margin and EPS from year one), Argentina JV with Arcor (deconsolidates, EPS-accretive over time); all closing in H2 2026.
- Margin: EDP margin down about 70 bps in H1 because inflation (energy, packaging) arrived before pricing; selective price increases roll out in Q3; hedging protects Specialized Nutrition and Waters more than dairy. Inventory rose about 250 million as security stocks against Middle East supply disruption, to unwind in the coming quarters; capex up €40-50m for medical nutrition and high protein.
- China: infant formula market "normalizing" after the Year of the Dragon, shares gaining via Essensis premiumisation; super-premium Nuturis launching in mainland China after Hong Kong; medical nutrition (tube feeding leadership, pediatrics, oral nutrition) "only at the start of the journey"; volume-based procurement is "business as usual".
- 2026 guidance confirmed: 3-5% LFL growth, recurring operating income faster than sales; no margin guidance ("our guidance is our guidance is our guidance").
- FY 2025 results conference call transcript (CEO Antoine de Saint-Affrique, CFO Juergen Esser)
- 2025, the first year of Renew Danone Chapter 2: like-for-like sales +4.5% with volume/mix +2.7%, recurring operating margin 13.4% (+44 bps, margin from operations +77 bps), recurring EPS €3.80 (+4.6%), free cash flow €2.8bn, ROIC 10.7% (+62 bps), dividend €2.25 (+5%); Q4 LFL +4.7%. Reported sales flat at €27.3bn after -4.4% currency.
- The call opened on the January 2026 infant formula recall (batches in Europe and the Middle East, under new authorities' requirements on cereulide): "food safety and quality are ... our top priority"; no significant stock returns, but shelf disruption at European retailers expected to cost 0.5-1% of group sales in Q1 2026, normalising in March; no products sold through official channels in China affected.
- Growth engines: Oikos Pro exceeded €1bn of revenue in the US; the Danone brand passed €1bn with high single-digit growth; Alpro is a €1bn platform; Aptamil grew double-digit and doubled in Vietnam; Fortimel and Nutrison form a fast-growing billion-euro medical nutrition platform; specialised channels (pharmacies, hospitals, home care) grew double-digit.
- Zones: Europe +2.3% with nine consecutive quarters of positive volume/mix, margin 12.0%; CNAO +11.7%, entirely volume/mix, margin 29.2%; North America +2.0% and only +0.7% in Q4, margin 11.0% (-39 bps) - "we are not where we should be"; Latin America +6.0%, margin up nearly 3 points to 6.4%; AMEA +5.6%.
- North America fixes: new Americas President Henri Bruxelles and deep leadership change (the head of the Alpro turnaround now runs US categories and creamers), Two Good clean-label creamers, Danimals relaunch, yogurt capacity added line by line; creamers to return to growth from Q2 2026 as comps ease. CEO: "I expect the end of not invented here and rapid movements in the US."
- Kate Farms plus Nutricia is now a $500m US medical nutrition platform growing strong double-digit, entering like-for-like from Q3 2026; the Australian dairy JV with Saputo (YoPRO, Activia, Ultimate, over €100m of revenue) is consolidated at 51%. Japan is a €400m EDP business growing strong double-digit on Oikos and Activia.
- Capex to rise from just under 4% to up to 4.5% of sales for high-protein and medical nutrition capacity; working capital at -10% of sales is "best-in-class". EDP margin target is "double-digit territory" but gross margin gains are being reinvested; whey and lactose inflation weighed on H2 gross margin.
- 2026 guidance: +3% to 5% like-for-like with recurring operating income growing faster than sales - "boringly consistent" since 2022.
- Fireside chat at the dbAccess Global Consumer Conference 2026 (Deutsche Bank) with CEO Antoine de Saint-Affrique and CFO Juergen Esser
- Backdrop unchanged despite the Middle East conflict and the Q1 infant formula recall: "the foods market is at a tipping point. People realize that they are what they eat"; ageing, mobility needs and cancer incidence drive demand. Q1 was "exceptional" but changes nothing in guidance or business model; the organisation is focused on volume/mix growth.
- Productivity is a "competitive edge" that funds reinvestment; pricing in response to inflation will be "as limited as possible and as selective as possible", with no large-scale restructuring ("silent restructuring when we need to"), using the Ukraine-war playbook.
- Mix comes from three sources: category mix (medical nutrition is accretive to growth and gross margin), innovation mix (high protein, Activia variants) and channel mix - hypermarkets went from about 55% of sales five years ago to 45% today, pharmacies carry better mix.
- US yogurt: per-capita consumption is about a third of Europe's; protein is "a trend that is here to stay", pushed by health, US government support for milk protein and GLP-1 access; next trends are gut health, kefir, pre- and probiotics and fibre. The Danone brand, "a bit of a sleeping beauty in the US" since 1942, is a billion-euro platform growing double-digit in Europe and Latin America and "has not been leveraged at all so far in the US". Improvement in North America will be "progressive ... quarter by quarter".
- US plant-based: Silk never got the Alpro repositioning from ingredient-led and anti-milk to benefit-led; new teams since January are deploying the Alpro playbook (the moderator referred to the announced closure of the New Jersey facility), and the CEO expects "progress in the next 12 months". Danone sold its stake in Lifeway but may return to kefir in the US.
- Adult medical nutrition grows high single to double-digit every quarter; Danone is no. 1 in China and Europe, investing in sales forces to reach tier 2-3 hospitals and pharmacies; with Kate Farms Danone has been "buying our route to market in the US". No interest in buying a large US infant formula business because of its liabilities: "ROIC, ROIC, ROIC".
- China infant formula: a market still worth about €20bn ten years on while births fell from 14 million to below 8 million; 1,000 players have become about 500, top three hold about 50% versus 70%+ elsewhere, so consolidation and science-led premiumisation (Essensis, Nuturis) continue; the Year of the Dragon was "a blip".
- ROIC went from 7.5% four years ago to over 10%; Kate Farms and Huel are expected to be EPS-accretive after 12 months. No margin-percentage guidance by design: managing to a KPI "you start cutting advertising, cutting in R&I".
- AI: everyone on Microsoft Copilot in a sandbox; AI in R&D (1,200 ferments), marketing, consumer care (a stool tracker), forecasting; Opole (Poland) is one of the most digital nutrition factories; AI image recognition for store checks; the group is planning reskilling for a decade in which "80% of the jobs would have changed". "We are not at peak protein."
- Fireside chat at an investor conference in Boston (September 8, 2026) with CEO Antoine de Saint-Affrique and CFO Juergen Esser, moderated by Warren Ackerman (Barclays)
- Renew Danone Chapter 2 in the CEO's words: "Danone is only doing one thing. We do health through food to as many people as possible", anchored in science; three moves - pivot how categories are seen (protein: Oikos Pro is $1bn-plus; gut health: Activia back to growth; plant-based to plant-powered: Alpro), broaden reach (large mass retail fell from about 60% of sales to closer to 40%, "the key driver of our resilience") and keep expanding via health-centred acquisitions. "We live in a world of constructive dissatisfaction."
- H2 2026 variables: Kate Farms enters like-for-like, the early-life nutrition recall fades, North America improves progressively; Mizone was a drag in Q2 and probably Q3 in a poor Chinese beverage season while Indonesia was strong. Esser: "very confident to deliver within our guidance in the short, medium and long term"; the CEO: the 3-5% band "gives us the flexibility to do the difficult right rather than the easy wrong".
- North America EDP is about 7% of group sales; capacity comes on "one line after the other" across 13 factories and should be a non-topic in five to six months; the plan is to play "a Danone game": protein in new formats, fibre and pre/probiotics with Activia, kefir in the US "in the coming months", and a revival of the Dannon brand with a new Greek approach at the start of 2027. Capacity takes 12-18 months to build; the CFO is "very bullish" on EDP globally (H1 +3.6%, Europe consistent, Japan and Latin America fast).
- Europe EDP: Activia revival is "a long haul journey" but back to growth on fibre and kefir; kefir will be a $100m-plus platform; Skyr combines naturalness and protein. US plant-based: Silk is being moved towards the Alpro model by a new team; "we need to see progress in a relatively short period of time."
- Infant formula recall: the Middle East bounced back in Q2 to prior distribution and shares; Europe is "a mixed bag" with a slower category and shares won in some countries and lost in others, expected to level out; in China social media drove a shift from international to China label, where Danone plays both.
- China: the infant formula market is still about €20bn with 7-8 million births versus 14 million before; premiumisation, urban penetration and consolidation (top three about 50%) still allow growth; Specialized Nutrition China should return to a mid-single-digit contribution; Danone went from no. 4-5 to co-leader in early life nutrition; Essensis is "probably halfway" to full distribution and Nuturis launches in waves; people over 60 in China will go from 250 million (2023) to 300 million (2030) and 350 million (2040), rebalancing the business towards medical nutrition.
- Early life nutrition is one-third China, one-third Europe, one-third rest of world; the latter grows high single to double-digit, is "very profitable" and 95% Aptamil, with investment in Latin America, the Middle East, India and South-East Asia. India has 23 million births a year: "If you want to be relevant in the long term, you need ... critical mass and presence there", built profitably.
- Margins: COGS inflation (packaging, energy, protein) is real and hard to size; levers are productivity, pricing "as we speak in many, many markets" and above all volume/mix; EDP margin should rise over the next years as pricing lands and North America recovers; the pivot from spoonable to drinkable and now "out of the fridge" (Huel, Alpro Meal to Go, ambient protein shakes) opens "a new, very profitable universe".
- Deals: Kate Farms gives a truly superior product and access to more than 1,500 hospitals; Huel brings a "Hueligans" community, 300-400 ads a month and influencer skills, with Danone adding science and distribution; MADE Group is "a mini-Danone" adding about 400 million in Australia, New Zealand and South-East Asia. The CEO reiterated he is "not interested" in the US part of a particular infant formula target because of legal and factory liabilities and a different business model.
Domande su Danone
Cosa fa Danone?
Danone produce latticini e prodotti vegetali, nutrizione infantile e medica e acque in bottiglia, con marchi come Activia, Oikos, Alpro, Aptamil, Nutricia ed evian.
Qual è il fatturato di Danone?
Le vendite sono state di 27.283 milioni di euro nel 2025 e di 13.936 milioni di euro nel H1 2026, in crescita del 3,5% a parità di perimetro.
Quanti dipendenti ha Danone?
Danone aveva 88.670 dipendenti al 31 dicembre 2025.
Chi guida Danone?
Antoine de Saint-Affrique è CEO, Juergen Esser è Deputy CEO e CFO e Gilles Schnepp presiede il Consiglio di amministrazione.
Qual è la strategia di Danone?
Renew Danone Chapter 2 sposta il portafoglio verso categorie legate alla salute come proteine, salute intestinale e nutrizione medica, amplia i canali ed espande la presenza negli Stati Uniti e nei mercati emergenti, puntando a una crescita a parità di perimetro del 3-5%.
Redatto da Tamtam a partire dai documenti pubblicati dall'azienda stessa, elencati sopra e letti per intero. I dati sono quelli di quei documenti, per i periodi che indicano. (2026-11-17)